Humacyte (NASDAQ:HUMA) Price Target Cut to $6.00 by Analysts at BTIG Research

Key Points

• Humacyte's price target has been reduced from $7.00 to $6.00 by BTIG Research while maintaining a "buy" rating, indicating a potential upside of 284.62% from its current price.
• The company is facing mixed analyst ratings, with six analysts giving it a "buy", while others have reduced their targets significantly, including HC Wainwright's cut to $3.00.
• Humacyte reported a loss of ($0.24) EPS for its last quarter, falling short of estimates, and its shares are currently trading around $1.56.

Humacyte (NASDAQ:HUMA - Get Free Report) had its price objective decreased by research analysts at BTIG Research from $7.00 to $6.00 in a research report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. BTIG Research's price objective points to a potential upside of 284.62% from the stock's current price.

A number of other brokerages have also issued reports on HUMA. HC Wainwright dropped their price target on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research report on Monday, October 6th. Barclays started coverage on shares of Humacyte in a research report on Wednesday, August 27th. They issued an "overweight" rating and a $3.50 price target for the company. Wall Street Zen lowered shares of Humacyte from a "hold" rating to a "sell" rating in a report on Sunday, August 17th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Humacyte presently has a consensus rating of "Moderate Buy" and an average price target of $8.71.

Humacyte Trading Down 4.9%

HUMA opened at $1.56 on Monday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The company's 50 day simple moving average is $1.73 and its two-hundred day simple moving average is $1.93. Humacyte has a 1-year low of $1.15 and a 1-year high of $6.77. The firm has a market capitalization of $247.06 million, a price-to-earnings ratio of -3.47 and a beta of 1.89.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.94 million. Analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 591,685 shares of Humacyte stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Brady W. Dougan sold 591,685 shares of Humacyte stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. In the last three months, insiders sold 4,482,090 shares of company stock valued at $7,466,382. 5.10% of the stock is currently owned by insiders.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lazari Capital Management Inc. purchased a new stake in Humacyte in the second quarter worth approximately $27,000. Prudential Financial Inc. bought a new stake in Humacyte in the second quarter valued at approximately $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte in the second quarter valued at approximately $28,000. Vanguard Personalized Indexing Management LLC bought a new stake in Humacyte in the second quarter valued at approximately $30,000. Finally, Valeo Financial Advisors LLC bought a new stake in Humacyte in the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.